US 20210269400A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2021/0269400 A1**

Silverman et al. (43) **Pub. Date: Sep. 2, 2021**

(54) **POTENT AND SELECTIVE HUMAN NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS**

(71) Applicant: **Northwestern University**, Evanston, IL (US)

(72) Inventors: **Richard B. Silverman**, Winnetka, IL (US); **Ha T. Do**, Evanston, IL (US)

(21) Appl. No.: **17/184,544**

(22) Filed: **Feb. 24, 2021**

Related U.S. Application Data

(63) Continuation of application No. PCT/US2020/019466, filed on Feb. 24, 2020.

(60) Provisional application No. 62/980,735, filed on Feb. 24, 2020.

Publication Classification

(51) **Int. Cl.**

C07D 213/73	(2006.01)
C07D 401/10	(2006.01)
C07D 401/06	(2006.01)
C07D 413/10	(2006.01)

(52) **U.S. Cl.**

CPC ***C07D 213/73*** (2013.01); ***C07D 413/10*** (2013.01); ***C07D 401/06*** (2013.01); ***C07D 401/10*** (2013.01)

(57) **ABSTRACT**

Disclosed are 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase (NOS). In particular, the field of the invention relates to 2-aminopyridine derivative compounds for use as inhibitors of neuronal nitric oxide synthase (nNOS), which are formulated as pharmaceutical compositions for treating diseases and disorders associated with nNOS such as Alzheimer's, Parkinson's, and Huntington's diseases, and amyotrophic lateral sclerosis, cerebral palsy, stroke/ischemic brain damage, and migraine headaches.